Infinium Pharmachem Ltd.
NNSE:INFINIUM286.00
INR
-10.50
(-3.54%)
Infinium Pharmachem Ltd.
NSE:INFINIUM
(National Stock Exchange of India)
Recent
price
286.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Infinium Pharmachem Limited manufactures and supplies iodine, iodine derivatives, and active pharmaceutical ingredients (APIs), with a portfolio exceeding 250 intermediates and more than 15 APIs; it also provides fully integrated contract research and manufacturing services (CRAMS) focused exclusively on iodine chemistry, including research and development, process optimization, custom synthesis under non-disclosure agreements, commercial-scale production, and customized packaging and labeling. The company serves diverse industries such as pharmaceuticals and biotech, specialty and performance chemicals, agrochemicals, nutraceuticals, animal feed, agriculture, paints and coatings, cosmetics, sanitation, electronics, textiles, and solar applications, with exports reaching over 15 countries globally from its manufacturing facilities in Gujarat, India. Founded in 2003 and headquartered near Sardar Patel Statue in Vallabh Vidyanagar, Anand, Gujarat, the company operates a GMP-compliant, FDA-approved, ISO 9001:2015 and ISO 14001:2015 certified plant in GIDC Sojitra, District Anand. In recent developments, Infinium Pharmachem completed the expansion and modernization of its iodine derivatives manufacturing facility in Gujarat's Anand District during fiscal year 2025, increasing installed production capacity to 1,800 metric tons per annum; it also launched a new API product line, Iohexol, in the same year. The company listed on the National Stock Exchange (NSE Emerge) in April 2023 following a successful initial public offering and issued a 1:1 bonus share ratio in September 2023; additionally, it approved investment in Infinium Healthcare Private Limited as a subsidiary to support a U.S. iodine extraction project and new facilities for contrast media intermediates used in PET scans, MRI, and X-rays, with a related project expected to commence commercial production by December 2024. These initiatives enhance backward integration, supply chain sustainability for iodine sourcing, and expansion into higher-value segments, while proposing preferential warrants issuance aggregating up to INR 44.5 crore for further growth.